Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause Disease progression? 286 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 286 reports of Disease progression have been filed in association with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (PLUVICTO). This represents 2.7% of all adverse event reports for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN.
286
Reports of Disease progression with LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN
2.7%
of all LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN reports
36
Deaths
18
Hospitalizations
How Dangerous Is Disease progression From LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN?
Of the 286 reports, 36 (12.6%) resulted in death, 18 (6.3%) required hospitalization.
Is Disease progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN. However, 286 reports have been filed with the FAERS database.
What Other Side Effects Does LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Cause?
General physical health deterioration (4,332)
Ill-defined disorder (3,600)
Death (1,179)
Malignant neoplasm progression (251)
Laboratory test abnormal (233)
Prostatic specific antigen increased (212)
Fatigue (177)
Anaemia (154)
Covid-19 (139)
Platelet count decreased (130)
What Other Drugs Cause Disease progression?
RITUXIMAB (7,282)
CYCLOPHOSPHAMIDE (7,100)
DOXORUBICIN (6,165)
VINCRISTINE (5,252)
PREDNISONE (5,096)
BEVACIZUMAB (4,653)
DEXAMETHASONE (4,545)
CARBOPLATIN (4,538)
CAPECITABINE (3,808)
ETOPOSIDE (3,776)
Which LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN Alternatives Have Lower Disease progression Risk?
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTETIUM OXODOTREOTIDE LU-177
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LUTROPIN ALFA
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYMECYCLINE
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYRICA
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN vs LYSERGIDE